Analysis of data from the Cancer Genome Atlas (TCGA) in melanoma has shown that PTEN deletions and loss-of-function mutations are more frequent in non-T-cell-inflamed tumors compared to T-cell-inflamed tissues, which correlates with poor responses to immunotherapy [50,127,128]. The gene discussed is PTEN; the disease is melanoma.